机构：[1]Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China[2]Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, China[3]Department of Health Statistics, Naval Medical University, Shanghai, China[4]Department of Gastrointestinal Surgery, The Second Affiliated Hospital, Wenzhou Medical University, Wenzhou, China[5]Department of Hepatobiliary Surgery, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China四川省人民医院[6]Department of Hepatobiliary Surgery, General Hospital of Northern Theater Command, Shenyang, China[7]Department of Hepatobiliary Surgery, Affiliated Hospital of Binzhou Medical College, Binzhou, China[8]Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China[9]The First Hospital of Jiaxing Affiliated Hospital of Jiaxing University, Jiaxing, China[10]Department of Hepatology, The Sixth People’s Hospital of Shenyang, Shenyang, China[11]CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China
Background: Preoperative hepatitis B virus (HBV) DNA level has been shown to correlate with the prognosis of patients with HBV-associated hepatocellular carcinoma (HCC) following liver resection, but its dynamic changes have not been reported. The aim of this longitudinal multicenter retrospective observational study was to describe the trajectory of HBV DNA after R0 liver resection in patients receiving antiviral therapy and to investigate its impact on clinical outcomes. Methods: This study included patients with HBV-related HCC from nine hospitals in China who received antiviral therapy and R0 hepatectomy between 2015 and 2016. A latent class growth mixed model (LCGMM) was applied to group the trajectories of HBV DNA changes. The relative importance of each variable to predict survival was evaluated using the chi 2. Results: Six hundred and eighty-four patients with HCC who met the inclusion exclusion criteria were included. Patients were divided into 5 trajectories of HBV DNA changes using LCGMM. By combining subgroups with similar survival characteristics, patients were reclassified into three groups: slow decline, slow zeroing, and fast zeroing group, the 5-year OS rates are 34.5 %, 53.0 %, 70.9 %, respectively. Multifactorial COX regression results showed that ALBI grade, HBV reactivation, cirrhosis, maximum tumor diameter, microvascular invasion, and HBV DNA trajectory groups were independent risk factors for OS. Conclusions: HBV DNA trajectories were associated with OS for patients with HBV-related HCC after R0 liver resection, and it is necessary to receive antiviral therapy and to monitor HBV status regularly.
基金：
National Key Research and Devel-opment Program of China [2022YFC2503700]
第一作者机构：[1]Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China[2]Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China[2]Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, China[*1]Eastern Hepatobiliary Surgery Hospital, Naval Medical University, 225 Changhai Road, Shanghai, 200433, China.[*2]Department of Hepatobiliary Surgery, the First Affiliated Hospital, Wenzhou Medical University, No. 2 Fuxue Lane, 325015, Wenzhou, Zhejiang Province, 325000, China.
推荐引用方式(GB/T 7714)：
Xiang Yan-Jun,Wang Kang,Qin Ying-Yi,et al.Trajectories of postoperative hepatitis B virus (HBV) DNA and HBV-related hepatocellular carcinoma outcomes[J].EJSO.2025,51(2):doi:10.1016/j.ejso.2024.109492.
APA：
Xiang, Yan-Jun,Wang, Kang,Qin, Ying-Yi,Liu, Zong-Han,Yu, Hong-Ming...&Cheng, Shu-Qun.(2025).Trajectories of postoperative hepatitis B virus (HBV) DNA and HBV-related hepatocellular carcinoma outcomes.EJSO,51,(2)
MLA：
Xiang, Yan-Jun,et al."Trajectories of postoperative hepatitis B virus (HBV) DNA and HBV-related hepatocellular carcinoma outcomes".EJSO 51..2(2025)
